A seroprevalence study of poliovirus antibody against a collection of recombinant and non-recombinant poliovirus vaccine strains in the population of southern Greece.
In this study, the serological status of the southern Greek population in the 1–10-year, 11–20-year, 21–30-year and 31–40-year age groups with regard to Sabin vaccine strains and a collection of 15 recombinant and four non-recombinant poliovirus vaccine strains was determined. For all three poliovirus types, the highest neutralization test (NT) titres were observed in the 1–10- year age group, indicating a good response to vaccination. In general, the serological status of the population of southern Greece with regard to poliovirus is better for types 1 and 2 than for type 3. The presence of the lowest NT titre in the 21– 30-year age group against poliovirus type 3 suggests the need for a booster dose of monovalent Sabin3 vaccine to ensure personal and herd immunity.
University of Thessaly, Department of Biochemistry & Biotechnology, Larissa, Greece.
V
V
Pliaka
I G A
IG
Ruether
Z
Z
Kyriakopoulou
P
P
Kioussi
E
E
Plakokefalos
M
M
Megalou
A
A
Pratti
S
S
Levidiotou-Stefanou
P
P
Markoulatos
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D006115:Greece / Q000453:epidemiology; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D007223:Infant; D009500:Neutralization Tests; D011051:Poliomyelitis / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control; D017955:Poliovirus / Q000276:immunology*; D011055:Poliovirus Vaccine, Oral / Q000008:administration & dosage / Q000276:immunology*; D023321:Poliovirus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D016036:Seroepidemiologic Studies; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
D000914:Antibodies, Viral; D011055:Poliovirus Vaccine, Oral; D023321:Poliovirus Vaccines; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic